First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

NCT05745350 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: Pembrolizumab, Plinabulin plus Etoposide and Platinum

Sponsor

Xiaorong Dong